Entera Bio (ENTX) Income from Continuing Operations (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Income from Continuing Operations of 3539000.0 in Q1 2026, down 16.84% on a QoQ basis from 3029000.0 in Q4 2025, and down 38.08% year-over-year from 5715473.85 in Q1 2025.
Entera Bio (ENTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 3539000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 38.08% year-over-year to 3539000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12568000.0 (down 23.92% YoY) and the FY2025 annual result came in at 11439000.0, down 19.89% from the prior year.
- Income from Continuing Operations slipped to 3539000.0 in Q1 2026, from 3029000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1995000.0 in Q4 2023 and troughed at 3784000.0 in Q1 2022.
- A 5-year average of 2748941.18 and a median of 2700000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 64.81% — and 2023, when it soared 42.12%.
- Tracing ENTX's Income from Continuing Operations over 5 years: stood at 3035000.0 in 2022, then jumped by 34.27% to 1995000.0 in 2023, then slipped by 18.2% to 2358000.0 in 2024, then fell by 28.46% to 3029000.0 in 2025, then decreased by 16.84% to 3539000.0 in 2026.
- Business Quant data shows ENTX's Income from Continuing Operations at 3539000.0 in Q1 2026, 3029000.0 in Q4 2025, and 3300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | -3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.54 Mn |
| Dec 31, 2025 | -3.03 Mn |
| Sep 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | -2.56 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.38 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.19 Mn |
| Dec 31, 2022 | -3.04 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.78 Mn |
| Dec 31, 2021 | -4.10 Mn |
| Sep 30, 2021 | -3.21 Mn |
| Jun 30, 2021 | -2.58 Mn |